加拿大宣布新投資以推動生物製造產業發展
Canada announces new investments to boost the biomanufacturing industry
截至2026年4月，加拿大正穩固其作為全球生物技術領導者的地位。
As of April 2026, Canada is cementing its position as a global leader in biotechnology.
這些投資從埃德蒙頓的主要設施資助到溫哥華的新專案，旨在推動加拿大從緊急應對狀態轉向持久的工業韌性。
These investments, ranging from major facility funding in Edmonton to new projects in Vancouver, aim to move Canada from a state of emergency response toward lasting industrial resilience.
雖然諸如位於魁北克的莫德納mRNA中心等最先進設施現正生產必需藥物，但仍存在一個重大挑戰：人才缺口。
While new state-of-the-art facilities—like the Moderna mRNA hub in Quebec—are now producing essential medicines, a significant challenge remains: the talent gap.
藉由專注於人才培育、靈活監管與策略性基礎建設，加拿大正將焦點從快速解決方案轉向成為醫療研究領域自給自足的強國。
By focusing on talent development, agile regulation, and strategic infrastructure, Canada is shifting its focus from quick fixes to becoming a self-reliant powerhouse in medical research.
